B. Riley Begins Coverage on Eton Pharmaceuticals (NASDAQ:ETON)

Analysts at B. Riley started coverage on shares of Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. The firm set a "buy" rating and a $21.00 price target on the stock. B. Riley's price objective points to a potential upside of 56.25% from the company's current price.

ETON has been the subject of a number of other reports. HC Wainwright raised their price objective on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Monday. Craig Hallum raised their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday.

Eton Pharmaceuticals Stock Up 11.9 %

Shares of NASDAQ ETON traded up $1.43 during trading on Friday, reaching $13.44. The company had a trading volume of 357,269 shares, compared to its average volume of 373,645. The business's 50-day moving average is $11.64 and its 200 day moving average is $7.35. The stock has a market cap of $350.13 million, a PE ratio of -61.09 and a beta of 1.38. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $15.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ETON. Wasatch Advisors LP bought a new stake in shares of Eton Pharmaceuticals during the 3rd quarter valued at about $1,431,000. Thompson Siegel & Walmsley LLC bought a new stake in Eton Pharmaceuticals during the second quarter valued at approximately $420,000. Aristides Capital LLC purchased a new stake in Eton Pharmaceuticals during the second quarter valued at approximately $658,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company's stock worth $390,000 after acquiring an additional 30,167 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company's stock worth $350,000 after acquiring an additional 41,469 shares during the last quarter. Institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.